In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation


Markers for cholesterol absorption are associated with In-stent-restenosis after coronary stenting in stable coronary artery disease: An Optical Coherence Tomography study

Session Poster Session 6

Speaker Oliver Weingaertner

Congress : ESC Congress 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Restenosis
  • Session type : Poster Session
  • FP Number : P5625

Authors : S Otto (Jena,DE), D Luetjohann (Bonn,DE), A Kerksiek (Bonn,DE), S Friedrichs (Bonn,DE), PC Schulze (Jena,DE), TC Poerner (Aachen,DE), O Weingaertner (Jena,DE)

S Otto1 , D Luetjohann2 , A Kerksiek2 , S Friedrichs2 , PC Schulze3 , TC Poerner4 , O Weingaertner3 , 1University Hospital Jena - Jena - Germany , 2University Hospital Bonn, Dept. of Clinical Pharmacology and Clinical Chemistry - Bonn - Germany , 3Clinic of Internal Medicine I, Cardiology Department - Jena - Germany , 4Marienhospital, Dept. of Internal Medicine and Cardiology - Aachen - Germany ,


Background: Plant sterols are suspected to exert atherosclerotic propensity. Modern drug-eluting stents are superior to bare metal stents but show a late catch up phenomenon for restenosis. Due to its superb resolution, optical coherence tomography (OCT) has the capability to identify and quantifiy very early patterns of in-stent proliferation. Studies have shown that in-stent neointimal proliferation is linked to late in-stent stenosis.

Purpose: This study aimed to analyze associations of plasma levels for markers of cholesterol homeostasis such as campesterol and sitosterol (markers for cholesterol absorption) as well as lanosterol (marker for cholesterol synthesis)and and their respective oxides with In-stent restenosis after stent deployment in stable coronary artery disease.

Methods: Plasma cholesterol was measured by gas chromatography-flame ionization detection. Plasma campesterol, sitosterol and lanosterol and their oxides were analyzed by gas chromatography-mass selective detection. In-stent proliferation (restenosis) was assessed after six months by OCT in 33 patients (21 males). A quantitative OCT algorithm was applied to each stent by steps of one mm and in-stent proliferation volumes and areas were calculated and normalized to stent length and area. In-stent proliferation can be measured by OCT as global volumes and focal areas. 

Results: No clinically significant restenosis or angiographic restenosis of > 30 % was observed at 6-month f/u. Mean cholesterol level was 166,5 ± 62,8 mg/dl and positively correlated with proliferation volume/cm (r=0.316, p=0.037) and absolute median proliferation area (r=0.322, p=0.029). Absolute median proliferation area and relative median proliferation area correlated positively with markers for cholesterol absorption such as campesterol-to-cholesterol (r=0.277, p=0.07 and 0.315, p=0.037) and sitosterol-to-cholesterol (r=0.237, p=0.092 and 0.322, p=0.034), whereas lanosterol (a marker for cholesterol synthesis) and its ratio to cholesterol correlated negatively with proliferation volumes and areas (p<0.05; table). Moreover, 7-beta-OH-campesterol correlated positively with proliferation volumes and areas (p<0.05, table). Also, the ratio of 7-beta-OH-campesterol-to-cholesterol correlated positively with proliferation volumes and areas (p<0.1,; table), but did not reach significance in this relatively small sample size. Morevover, there was a positive association of the sum of all plant sterol oxides with In-stent restenosis (data not shown).

Conclusions: In this hypothesis-generating study, in-stent proliferation assessed by OCT at six months follow-up was positively associated with markers for cholesterol absorption and negatively associated with markers for cholesterol synthesis. Larger studies will have to evaluate whether patients with high cholesterol absorption might benefit in particular from combined-lipid-lowering therapy with a statin and a cholesterol absorption Inhibitor.

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are